Frazier Life Sciences Acquisition Corp. II Completes $75 Million IPO

Frazier Life Sciences Acquisition Corp. II has completed its initial public offering of 7,500,000 Class A ordinary shares at a price of $10.00 per share, raising a total of $75,000,000. The special purpose acquisition company, listed on The Nasdaq Capital Market under the ticker symbol FLSC, began trading on October 14, 2026.

The Palo Alto-based entity was formed to execute a business combination, such as a merger, asset purchase, or reorganization, with one or more other entities. While the company may pursue opportunities in any industry or geographical location, it intends to leverage its management team's experience to identify promising targets within the biotechnology sector. The stated goal is to finance a company capable of developing new therapies for patients while creating value for shareholders.

Albert Cha, MD, PhD, serves as Chief Executive Officer, Ben Palleiko chairs the Board of Directors, and Kevin Li, M.D., is Chief Business Officer. The company is sponsored by Frazier Life Sciences Holdings II, LLC, an affiliate of Frazier Life Sciences Management, L.P.

Jefferies acted as the sole book-running manager for the offering. The securities were offered only through a prospectus, which is available from Jefferies LLC in New York or via the Securities and Exchange Commission's website. The SEC declared the registration statement for these securities effective on October 13, 2026.

The company notes that no assurance can be given that the proceeds of the offering will be used as indicated. Forward-looking statements regarding the search for an initial business combination are subject to conditions beyond the company's control, as detailed in the Risk Factors section of its registration statement filed with the SEC. The company undertakes no obligation to update these statements except as required by law.